Last month Mylan Laboratories announced that they had received an "approvable" letter from the FDA for EMSAM™ (selegiline transdermal system), an antidepressant patch. It has been speculated that this form of delivery will help bypass some of the side-effects that have pushed MAOIs out of favor. This could be good news for those with atypical depression, who may respond best to MAOIs.
Comments
No comments yet. Leave a Comment
